At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

Grassmuno – also known as Grass MATA MPL – is also the first subcutaneous grass pollen allergy immunotherapy to be cleared by ...

Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...

Benger will take over from Roberts – who was named CEO in 2021 and announced her decision to step down in the summer – on ...

The rise of NP/PA influence is not a passing trend; it is a structural realignment of US healthcare. These clinicians are the ...

The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...

The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...

Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...